ATHERTON, Calif.--(BUSINESS WIRE)--WellTheory, a first-of-its-kind virtual solution for the 50 million Americans suffering with autoimmune disease, launched an enterprise solution today that will ...
Kim Stoeger and Brooke Knowles from Nutritional Healing join the Living with Amy show to talk about how they can help people with autoimmune diseases. For more information call 920-HEALING or reach ...
Arialys Therapeutics Inc. launched this month with $58 million in seed funding, an experimental compound it is developing for autoimmune encephalitis and autoimmune psychosis, and high aspirations for ...
Rheumatoid arthritis is a prevalent autoimmune condition affecting millions globally, causing joint pain, swelling, and reduced mobility. BioNxt is leveraging its expertise in sublingual (thin-film) ...
This eBook from ACROBiosystems offers a clear, in-depth look at how autoimmune drugs are developed, breaking down disease mechanisms, emerging therapies, and promising targets across major autoimmune ...
Sino Biological provides comprehensive solutions for autoimmune diseases, offering a wide range of research reagents for nearly 50 diseases. Our portfolio includes autoimmune disease target reagents ...
AliveDx receives three IVDR CE Marks for its automated, multiplexed MosaiQ ® solution, enabling faster diagnosis of Connective Tissue Diseases (CTD) - The MosaiQ CENP-B microarray immunoassay designed ...
BioNxt's lead pipeline product for MS is a proprietary sublingual (thin-film) formulation of Cladribine, offering an innovative alternative to traditional oral tablets. This next-generation delivery ...
Leading our In Focus on autoimmune disease research solutions, this video gives an introduction to autoimmune diseases, the techniques used for detecting them, targets for drug development and ...
VANCOUVER, BC / ACCESSWIRE / November 25, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to announce the expansion of its next-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results